Schizophrenia News

Brilaroxazine, a potential new treatment for schizophrenia, significantly improved symptoms and was well-tolerated in a pivotal phase 3 trial, according to a press release from its manufacturer.

Evenamide, an investigational drug for treatment-resistant schizophrenia, was linked with “increasing, sustained and clinically significant” symptom improvements in a recent study, according to a manufacturer press release.

Published results showed no statistically significant associations between mental health conditions, such as depression, anxiety, bipolar disorder, trauma and schizophrenia, and outcomes after total joint arthroplasty.

Karuna Therapeutics Inc. has submitted a new drug application to the FDA for KarXT, its investigational muscarinic antipsychotic for the treatment of schizophrenia.

A woman diagnosed with schizophrenia and psychosis who was nonverbal and nonresponsive for 2 decades recently “woke” after treatment with pulse steroids and cyclophosphamide.

Atopic dermatitis was associated with increased odds for schizophrenia and schizoaffective disorder, according to a study published in Archives of Dermatological Research.

Two phase 3 studies of a once-daily treatment for schizophrenia failed to meet their primary endpoints, with developers pointing to placebo effects and disruption from the COVID-19 pandemic to possibly explain the drug’s performance.

Symptom dimensions within bipolar disorder may have distinct causes, supporting the hypothesis that genetic heterogeneity underpins clinical heterogeneity, according to a study published in The Lancet Psychiatry.

MIAMI BEACH, Fla. — Treatment with KarXT reduced symptom severity for those with schizophrenia and acute psychosis compared with placebo, according to research presented at the American Society of Clinical Psychopharmacology annual meeting.

SAN FRANCISCO — Among people with schizophrenia, lifetime duration of cannabis use was associated with cognitive function, according to a poster presented at the American Psychiatric Association annual meeting.